1h Free Analyst Time
The human immunoglobulin market is forecasted to grow by USD 9.69 billion during 2023-2028, accelerating at a CAGR of 10.11% during the forecast period. The report on the human immunoglobulin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increase in plasma donation, rising prevalence of immunodeficiency disorders, and growing geriatric population.
The human immunoglobulin market is segmented as below:
By Application
- Autoimmune disorders
- Hematology diseases
- Inflammatory diseases
- Infectious diseases
- Others
By End-user
- Hospitals
- Clinics
- Ambulatory surgical center (ASC)
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the human immunoglobulin market covers the following areas:
- Human immunoglobulin market sizing
- Human immunoglobulin market forecast
- Human immunoglobulin market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Application
9 Market Segmentation by End-user
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global human immunoglobulin market: ADMA Biologics Inc., argenx SE, Baxter International Inc., Bio Products Laboratory Ltd., CSL Ltd., Emergent BioSolutions Inc., Grifols SA, Hualan Biological Vaccine Inc., Kamada Ltd., Kedrion Spa, LFB SA, Octapharma AG, Pfizer Inc., Prothya Biosolutions Netherlands BV, Sanquin, Shanghai RAAS Blood Products Co. Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd, and Takeda Pharmaceutical Co. Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is rising research and development in human immunoglobulin."
According to the report, one of the major drivers for this market is the increase in plasma donation.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ADMA Biologics Inc.
- argenx SE
- Baxter International Inc.
- Bio Products Laboratory Ltd.
- CSL Ltd.
- Emergent BioSolutions Inc.
- Grifols SA
- Hualan Biological Vaccine Inc.
- Kamada Ltd.
- Kedrion Spa
- LFB SA
- Octapharma AG
- Pfizer Inc.
- Prothya Biosolutions Netherlands BV
- Sanquin
- Shanghai RAAS Blood Products Co. Ltd.
- Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd
- Takeda Pharmaceutical Co. Ltd.
